$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000123252418000133 Filed on August 07, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$500.5M	$394.4M
YoY Change	26.9%	3.47%
Cost Of Revenue	$34.70M	$28.70M
YoY Change	20.91%	19.58%
Gross Profit	$461.4M	$361.0M
YoY Change	27.81%	1.65%
Gross Profit Margin	92.19%	91.53%
Selling, General & Admin	$158.6M	$132.3M
YoY Change	19.84%	7.92%
% of Gross Profit	34.37%	36.66%
Research & Development	$56.13M	$40.16M
YoY Change	39.78%	2.73%
% of Gross Profit	12.17%	11.12%
Depreciation & Amortization	$58.80M	$29.30M
YoY Change	100.68%	0.0%
% of Gross Profit	12.74%	8.12%
Operating Expenses	$347.3M	$229.3M
YoY Change	51.42%	7.96%
Operating Profit	$153.2M	$165.0M
YoY Change	-7.18%	-2.19%
Interest Expense	-$19.65M	-$18.29M
YoY Change	7.39%	50.93%
% of Operating Profit	-12.82%	-11.08%
Other Income/Expense, Net
YoY Change
Pretax Income	$129.4M	$141.3M
YoY Change	-8.41%	-9.76%
Income Tax	$36.50M	$35.52M
% Of Pretax Income	28.2%	25.13%
Net Earnings	$92.32M	$105.6M
YoY Change	-12.58%	-7.77%
Net Earnings / Revenue	18.45%	26.78%
Basic Earnings Per Share	$1.53	$1.76
Diluted Earnings Per Share	$1.50	$1.72
COMMON SHARES
Basic Shares Outstanding	60.18M shares	60.10M shares
Diluted Shares Outstanding	61.44M shares	61.46M shares

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$815.1M	$319.2M
YoY Change	155.36%	-65.17%
Cash & Equivalents	$485.1M	$239.2M
Short-Term Investments	$330.0M	$80.00M
Other Short-Term Assets	$55.63M	$36.45M
YoY Change	52.64%	38.88%
Inventory	$46.16M	$39.66M
Prepaid Expenses	$33.59M	$28.43M
Receivables	$278.4M	$238.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.307B	$662.5M
YoY Change	97.27%	-46.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$188.1M	$136.6M
YoY Change	37.66%	46.16%
Goodwill	$936.5M	$926.3M
YoY Change	1.1%	39.96%
Intangibles	$2.842B	$3.033B
YoY Change	-6.29%	133.18%
Long-Term Investments
YoY Change
Other Assets	$23.40M	$16.64M
YoY Change	40.67%	-55.04%
Total Long-Term Assets	$4.042B	$4.142B
YoY Change	-2.4%	86.79%
TOTAL ASSETS
Total Short-Term Assets	$1.307B	$662.5M
Total Long-Term Assets	$4.042B	$4.142B
Total Assets	$5.349B	$4.804B
YoY Change	11.34%	39.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$31.38M	$28.53M
YoY Change	9.99%	0.43%
Accrued Expenses	$258.8M	$169.7M
YoY Change	52.5%	7.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$33.39M	$36.09M
YoY Change	-7.5%	-3.75%
Total Short-Term Liabilities	$348.0M	$250.4M
YoY Change	38.96%	10.44%
LONG-TERM LIABILITIES
Long-Term Debt	$1.558B	$1.636B
YoY Change	-4.74%	43.28%
Other Long-Term Liabilities	$205.7M	$144.7M
YoY Change	42.19%	53.61%
Total Long-Term Liabilities	$1.764B	$1.780B
YoY Change	-0.92%	44.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$348.0M	$250.4M
Total Long-Term Liabilities	$1.764B	$1.780B
Total Liabilities	$2.112B	$2.031B
YoY Change	3.99%	38.86%
SHAREHOLDERS EQUITY
Retained Earnings	$1.000B	$690.2M
YoY Change	44.94%	112.46%
Common Stock	$2.037B	$1.721B
YoY Change	18.4%	6.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.870B	$2.201B
YoY Change
Total Liabilities & Shareholders Equity	$5.349B	$4.804B
YoY Change	11.34%	39.32%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	$92.32M	$105.6M
YoY Change	-12.58%	-7.77%
Depreciation, Depletion And Amortization	$58.80M	$29.30M
YoY Change	100.68%	0.0%
Cash From Operating Activities	$191.9M	$135.1M
YoY Change	42.04%	0.07%
INVESTING ACTIVITIES
Capital Expenditures	-$115.3M	-$10.10M
YoY Change	1041.58%	-93.42%
Acquisitions
YoY Change
Other Investing Activities	-$75.40M	-$20.00M
YoY Change	277.0%	-62.05%
Cash From Investing Activities	-$190.6M	-$30.10M
YoY Change	533.22%	-85.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	28.90M	-214.5M
YoY Change	-113.47%	468.97%
NET CHANGE
Cash From Operating Activities	191.9M	135.1M
Cash From Investing Activities	-190.6M	-30.10M
Cash From Financing Activities	28.90M	-214.5M
Net Change In Cash	30.20M	-109.5M
YoY Change	-127.58%	0.46%
FREE CASH FLOW
Cash From Operating Activities	$191.9M	$135.1M
Capital Expenditures	-$115.3M	-$10.10M
Free Cash Flow	$307.2M	$145.2M
YoY Change	111.57%	-49.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60409148	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
	dei	Trading Symbol TradingSymbol	JAZZ
CY2017Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	2181000	USD
CY2018Q2	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	5606000	USD
CY2017Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	2827000	USD
CY2018Q2	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1767000	USD
CY2017Q4	jazz	Accrued Interest AccruedInterest	7297000	USD
CY2018Q2	jazz	Accrued Interest AccruedInterest	7430000	USD
CY2017Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3002000	USD
CY2018Q2	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	6068000	USD
CY2017Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	81368000	USD
CY2018Q2	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	86921000	USD
CY2017Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2018Q2	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
	jazz	Contract With Customer Liability Cumulative Effect Of New Accounting Principle ContractWithCustomerLiabilityCumulativeEffectOfNewAccountingPrinciple	2240000	USD
CY2017Q2	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	28672000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	53737000	USD
CY2018Q2	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	34714000	USD
CY2017Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	68633000	USD
CY2017Q2	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
CY2018Q2	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-1425000	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-1425000	USD
CY2018Q2	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2018Q2	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
	jazz	Payments For Proceeds From Tenant Allowance Financing Activities PaymentsForProceedsFromTenantAllowanceFinancingActivities	0	USD
	jazz	Payments For Proceeds From Tenant Allowance Financing Activities PaymentsForProceedsFromTenantAllowanceFinancingActivities	-1253000	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	2000000	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	1548000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	2670000	USD
CY2017Q4	jazz	Sales Return Reserve SalesReturnReserve	3651000	USD
CY2018Q2	jazz	Sales Return Reserve SalesReturnReserve	2696000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	19071000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	67058000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24368000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	31379000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	224129000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	278441000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	54930000	USD
CY2018Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43824000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	198779000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	258794000	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3189000	USD
CY2018Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	4221000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3213000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3596000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8058000	USD
CY2018Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7614000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41203000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43552000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-140878000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-168228000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-140825000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1935486000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2037091000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	16320000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	16023000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52602000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50570000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27260000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52453000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26312000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50615000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17422000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	34991000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	21466000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	42101000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11379000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21504000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26186000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51851000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54959000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107966000	USD
CY2017Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	42896000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	42896000	USD
CY2017Q4	us-gaap	Assets Assets	5123672000	USD
CY2018Q2	us-gaap	Assets Assets	5348967000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	968277000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	1306931000	USD
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2018Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	78033000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	601035000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	815081000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	601035000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	815081000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	365963000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239213000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386035000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	485081000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-126750000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	99046000	USD
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	1300000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	195198000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	299199000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22861000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	110909000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	24733000	USD
CY2018Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18744000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3749000	USD
CY2017Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-298000	USD
CY2018Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1817734000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7673000	USD
CY2018Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	10779000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	34559000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	40997000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35154000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-29956000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-32228000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	383472000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	354932000	USD
CY2018Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	386605000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8618000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6456000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7498000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16115000	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12288000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14995000	USD
	us-gaap	Depreciation Depreciation	6223000	USD
	us-gaap	Depreciation Depreciation	7457000	USD
CY2017Q4	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	17633000	USD
CY2018Q2	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	7075000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5409000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5400000	USD
CY2017Q4	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	5409000	USD
CY2018Q2	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	5400000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.76
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.20
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.30
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.13
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.26
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	3499000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1148000	USD
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.251
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.252
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.282
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.286
CY2017Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	9838000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	17462000	USD
CY2018Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	4846000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8514000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	578017000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	562383000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3408566000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3259753000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2830549000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2697370000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5427000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6891000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2697000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4425000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-457000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-115000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	947537000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	936493000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-11044000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	141322000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	257154000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	129431000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	194905000	USD
CY2017Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-203000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-364000	USD
CY2018Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-586000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-923000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35515000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64675000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36524000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55670000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5347000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7371000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3038000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54356000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2487000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-3285000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-33072000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	60108000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25320000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3749000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5879000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8938000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2267000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3583000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	15533000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	13955000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	870000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5268000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1363000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1330000	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1261000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1256000	shares
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3557144000	USD
CY2018Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3404660000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2979127000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2842277000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18294000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-37138000	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-19646000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-40251000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	24011000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17945000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	43245000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	46156000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3542000	USD
CY2018Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4244000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15692000	USD
CY2018Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	23967000	USD
CY2017Q4	us-gaap	Investments Investments	215000000	USD
CY2018Q2	us-gaap	Investments Investments	330000000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5123672000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5348967000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	293947000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	347950000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	1581038000	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	1591701000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	40605000	USD
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	33387000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	1092493000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	33387000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	608387000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33387000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	33387000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	16693000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1540433000	USD
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1558314000	USD
CY2017Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	0	USD
CY2018Q2	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	57353000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-396155000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18702000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33725000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237383000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	299631000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	353983000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	105604000	USD
	us-gaap	Net Income Loss NetIncomeLoss	192115000	USD
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-27552000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	229343000	USD
	us-gaap	Operating Expenses OperatingExpenses	469256000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	92321000	USD
	us-gaap	Net Income Loss NetIncomeLoss	138312000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	347280000	USD
	us-gaap	Operating Expenses OperatingExpenses	704086000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	165043000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	301183000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	153199000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	241006000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23654000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	26298000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76686000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	55634000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16419000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23404000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-726000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1348000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1354000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	4558000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	-104000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	-193000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	193000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	651000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	90320000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	108432000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-70814000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31961000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	89594000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	107084000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-69460000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-27403000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	176608000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	205731000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10996000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	30859000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55561000	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	6406000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16320000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16023000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	111102000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	120000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	500000000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	11725000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	11281000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23182000	USD
CY2018Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33586000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	19071000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	67058000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	100000000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	385000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	211283000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	231638000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	170080000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188086000	USD
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-149000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	350000000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	18047000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9023000	USD
CY2017Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2000000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2000000	USD
CY2018Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40157000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85085000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56132000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118799000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	917956000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1000356000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	917605000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	394386000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	770439000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500479000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	945092000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	132328000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	276583000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	158579000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	365792000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	52453000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	50615000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	30859000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	55561000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1877339000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	2201032000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2713097000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	2869752000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	21577000	USD
CY2018Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	17934000	USD
CY2018Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	62600000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61463000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61321000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61438000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61309000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60100000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59991000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60177000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60053000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$162.5 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the net liability fair value of outstanding foreign exchange forward contracts was </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not material.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-18-000133-index-headers.html	Edgar Link	pending
0001232524-18-000133-index.html	Edgar Link	pending
0001232524-18-000133.txt	Edgar Link	pending
0001232524-18-000133-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20180630.xml	Edgar Link	completed
jazz-20180630.xsd	Edgar Link	pending
jazz-20180630_cal.xml	Edgar Link	unprocessable
jazz-20180630_def.xml	Edgar Link	unprocessable
jazz-20180630_lab.xml	Edgar Link	unprocessable
jazz-20180630_pre.xml	Edgar Link	unprocessable
jazz2018q2doc.htm	Edgar Link	pending
jazzq22018ex101.htm	Edgar Link	pending
jazzq22018ex102.htm	Edgar Link	pending
jazzq22018ex103.htm	Edgar Link	pending
jazzq22018ex104.htm	Edgar Link	pending
jazzq22018ex105.htm	Edgar Link	pending
jazzq22018ex106.htm	Edgar Link	pending
jazzq22018ex311.htm	Edgar Link	pending
jazzq22018ex312.htm	Edgar Link	pending
jazzq22018ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2018 Q2 Form 10-Q Financial Statement

#000123252418000133 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2018 Q2 Form 10-Q Financial Statement

#000123252418000133 Filed on August 07, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz